EP0718286B1 - Dérivé de 3-alkoxybenzylpiperidine utiles comme agents mélatonergique - Google Patents

Dérivé de 3-alkoxybenzylpiperidine utiles comme agents mélatonergique Download PDF

Info

Publication number
EP0718286B1
EP0718286B1 EP95402861A EP95402861A EP0718286B1 EP 0718286 B1 EP0718286 B1 EP 0718286B1 EP 95402861 A EP95402861 A EP 95402861A EP 95402861 A EP95402861 A EP 95402861A EP 0718286 B1 EP0718286 B1 EP 0718286B1
Authority
EP
European Patent Office
Prior art keywords
methyl
methoxyphenyl
fluoro
piperidine
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP95402861A
Other languages
German (de)
English (en)
Other versions
EP0718286A1 (fr
Inventor
Ronald J. Mattson
Daniel J. Keavy
John D. Catt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of EP0718286A1 publication Critical patent/EP0718286A1/fr
Application granted granted Critical
Publication of EP0718286B1 publication Critical patent/EP0718286B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom

Definitions

  • the invention pertains to novel 3-alkoxybenzylpiperidine derivatives (i.e., amides and ureas of 3- and 4-benzylpiperidines) having drug and bio-affecting properties and to their preparation, pharmaceutical formulations containing them, and use thereof in the manufacture of a medicament for treating certain medical disorders.
  • the invention concerns N-acyl 3-benzylpiperidines and N-amido 4-benzylpiperidines having a meta-alkooxy substituent in the phenyl ring of the benzyl moiety. These compounds possess melatonergic properties that should make them useful in treating certain medical disorders.
  • Melatonin ( i ; N-acetyl-5-methoxytryptamine) is a hormone which is synthesized and secreted primarily by the pineal gland. Melatonin levels show a cyclical, circadian pattern with highest levels occurring during the dark period of a circadian light-dark cycle. Melatonin is involved in the transduction of photoperiodic information and appears to modulate a variety of neural and endocrine functions in vertebrates, including the regulation of reproduction, body weight and metabolism in photoperiodic mammals, the control of circadian rhythms, and the modulation of retinal physiology.
  • melatonin agonists should be particularly useful for the treatment of sleep disorders and other chronobiological disorders.
  • Melatonin agonists would also be useful for the further study of melatonin receptor interactions as well as in the treatment of conditions affected by melatonin activity, such as depression, work-shift syndrome, sleep disorders, glaucoma, reproduction, cancer, immune disorders, neuroendocrine disorders, and a variety of sleep disorders.
  • amide structures Aside from simple indole derivatives of melatonin itself, various amide structures have been prepared and their use as melatonin ligands disclosed. In general these amide structures can be represented as: wherein Z is an aryl or heteroaryl system attached by a two carbon chain to the amide group.
  • R is hydrogen or OR 4 wherein R 4 is, inter alia , hydrogen, alkyl, cycloalkyl, or cycloalkylalkyl; R 1 is hydrogen or COOR 5 wherein R 5 is hydrogen or alkyl; R 2 is hydrogen or alkyl; X is NH or a bond; and R 3 is, inter alia , alkyl, alkenyl, or cycloalkyl.
  • R is hydrogen or OR 3 wherein R 3 is, inter alia , hydrogen, lower alkyl, or cycloalkyl; R 1 is hydrogen or lower alkyl; X is oxygen or sulfur; and R 2 is, inter alia , lower alkyl or cycloalkyl.
  • arylalkyl(thio)amides 8 as melatonergic ligands, wherein R 1 is hydrogen or lower alkyl; R 2 is hydrogen, halogen, or lower alkyl; R 3 and R 4 are identical or different groups including, inter alia , hydrogen, halogen, or lower alkyl; R 5 is hydrogen or lower alkyl; X is sulfur or oxygen and R 7 is, inter alia , lower alkyl or alkenyl.
  • Jacobs et al. in European Patent Application 532177A disclose compounds of type 10 as intermediates in the synthesis of 11 . Neither 9 nor 10 were described as having melatonergic properties.
  • the present invention is concerned with compounds of Formula I, which possess melatonergic properties and thus have potential utility in the treatment of conditions affected by melatonin activity.
  • R 1 is C 1-4 alkyl, C 2-4 alkenyl, C 3-6 cycloalkyl or NR 7 R 8 where R 7 and R 8 are independently selected from hydrogen and C 1-4 alkyl, but R 7 and R 8 cannot both be hydrogen;
  • R 2 , R 3 and R 4 are independently hydrogen or C 1-4 alkyl;
  • R 5 is hydrogen, C 1-4 alkyl, halogen or trifluoromethyl;
  • R 6 is C 1-4 alkyl;
  • X is either oxygen or sulfur; the benzyl group is appended to either the 3- or 4- position of the piperidine ring.
  • halogen denotes fluorine, chlorine, bromine and iodine
  • C 1-4 alkyl refers to straight and branched chain saturated carbon radicals of from 1 to 4 carbon atoms, e.g. methyl, ethyl, n-propyl, 1-methyl-1-ethyl, 1-methyl-1-propyl, ;
  • alkenyl refers to straight and branched carbon radicals of from 2 to 4 carbon atoms containing a carbon-carbon double bond, e.g. ethenyl, propenyl;
  • cycloalkyl pertains to homocyclic rings of from 3 to 6 carbon atoms, e.g.
  • NR 7 R 8 is meant alkylamino groups wherein R 7 and R 8 are independently selected from H and C 1-4 alkyl, with the proviso that R 7 and R 8 are not both hydrogen.
  • the present invention pertains to compounds of Formula I in which R 2 , R 3 and R 4 are hydrogen; R 5 is either hydrogen or 2-fluoro, with the proviso that when R 5 is 2-fluoro the alkoxy group is para to the fluoro group; and R 6 is methyl.
  • Preferred compounds of Formula I are those wherein X is O; R 2 , R 3 and R 4 are all H; R 5 is H or 2-fluoro, and R 6 is CH 3 .
  • More preferred compounds of the present invention include those in the following list:
  • the compounds of Formula I can be prepared as depicted in the following General Scheme.
  • the groups R 1 , R 2 , R 3 and X shown in Scheme 1 are as defined hereinabove.
  • the additional symbol M appearing in Scheme 1 represents a metal such as magnesium or lithium of a Grignard or organolithium reagent respectively.
  • compounds of Formula I also encompass all pharmaceutically acceptable solvates, hydrates being the preferred solvates.
  • the present invention also includes stereoisomers as well as optical isomers, e.g. mixtures of enantiomers as well as individual enantiomers and diastereomers, which arise as a consequence of structural asymmetry in certain compounds of the instant series. Separation of the individual isomers is accomplished by application of various methods which are well known to practitioners of the art.
  • the compounds of the present invention have affinity for receptors of the endogenous pineal hormone, melatonin, as determined in a receptor binding assay, and exhibit partial agonist activity as determined by a functional assay; the biological tests are described hereinbelow.
  • melatonin is involved in the regulation of a variety of biological rhythms and exerts its biological effects via interaction with specific receptors.
  • administration of melatonin agonists are of clinical utility in the treatment of various conditions regulated by melatonin activity. Such conditions include depression, jet-lag, work-shift syndrome, sleep disorders, glaucoma, some disorders associated with reproduction, cancer, immune disorders and neuroendocrine disorders.
  • the systemic administration and dosing regimen of compounds of Formula I can be considered to be done in a manner similar to that described for melatonin itself.
  • the dosage and dosage regimen must be adjusted using sound professional judgment and taking into consideration such variables as the age, body weight, sex and physical condition of the recipient, the route of administration and the nature of the illness being treated.
  • Oral, transdermal, subcutaneous, intravenous, intramuscular, rectal, buccal, intranasal, and ocular routes of administrations may be used.
  • One or more of the compounds of the invention is mixed with pharmaceutically acceptable amounts of one or more conventional pharmaceutical excipients to produce a formulation to be administered by the desired route.
  • such formulations will contain one or several carriers or diluents.
  • Useful carriers include solids, semi-solids and liquids which have miscibility, or other compatibility, with the active agent(s) so that they can deliver same to a patient or host.
  • Suitable carriers include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methyl- and propylhydroxybenzoates, talc, magnesium stearate, mineral oil and the like. Mixtures are operable.
  • excipients include lubricants, wetting agents, gellants, emulsifiers, preservatives, colorants, perfumes, flavor enhancers, drying agents and the like. Mixtures can be employed.
  • compositions which include the compounds of the invention will contain from about 0.10 to about 10% of active compounds(s) and 99.90 to 90%, or other suitable amounts, of excipient(s).
  • Dosage levels will be dictated by the patient's needs and by the medical judgment of the treating physician. Generally, however, dosages of about 0.1 mg to about 100 mg per day are useful to treat sleep or circadian rhythm disorders.
  • the compounds of the invention are used in the manufacture of a medicament for treating certain medical disorders.
  • one or more dosages of the medicament containing the compound of the invention are administered to an host, preferably a mammalian, e.g. a human host in need of such a medicament.
  • NMR nuclear magnetic resonance
  • ⁇ parts per million
  • TMS tetramethylsilane
  • the relative area reported for NMR signals at various chemical shifts corresponds to the number of hydrogen atoms of a particular type in the molecule.
  • the multiplicities of the signals are reported as broad singlet (bs), singlet (s), doublet (d), triplet (t), quartet (q) or multiplet (m).
  • the NMR spectra were obtained using solutions of the compounds in either deuterodimethylsulfoxide (DMSO-d 6 ) or deuterochloroform (CDCl 3 ).
  • Infrared (IR) spectral descriptions include only absorption wave numbers (cm -1 ) having functional group identification value and IR determinations were made using potassium bromide (KBr) as diluent. The elemental analyses are reported as percent by weight. Table 1 lists the IR carbonyl stretching frequencies and elemental analyses of all the specifically claimed compounds of Formula I.
  • Butyllithium (47.5 ml of 2.22M solution, 106 mmol) was added slowly to a solution of pentamethyldiethylenetriamine (15 ml) and 4-fluoroanisole (12.61 g, 0.1 mol) in THF (150 ml) at -70°C. The solution was stirred for 2 hr at -75°C and a solution of pyridine-4-carboxaldehyde (9.55 ml, 0.1 mol) in THF was added at -75°C. The mixture was allowed to warm to 25°C slowly and then quenched with ammonium chloride solution. The mixture was diluted with ethyl acetate and the organic layer was separated.
  • Process # 1 A specific example of Process # 1 is as follows:
  • Process # 3 A specific example of Process # 3 is as follows:
  • N-Ethyl-4-[(2-fluoro-5-methoxyphenyl)methyl]-1-piperidinecarboxamide A magnetically stirred solution of 4-[(2-fluoro-5-methoxyphenyl)methyl]-piperidine (0.895 g, 4.01 mmol) in anhydrous dichloromethane (15 mL) at 5 °C was treated dropwise with a solution of ethyl isocyanate (0.320 g, 4.41 mmol) in dry dichloromethane (5 mL). The solution was stirred 0.5 h at 5 °C, allowed to warm to room temperature and stirred for 48 h.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (10)

  1. Composé de formule I
    Figure 00320001
    dans laquelle
    R1 est choisi parmi alkyle inférieur C1-4, alcényle C2-4, cycloalkyle C3-6, et NR7R8 où R7 et R8 sont indépendamment choisis parmi l'hydrogène et un alkyle C1-4 à la condition que R7 et R8 ne soient pas tous les deux hydrogène;
    R2, R3 et R4 sont indépendamment choisis parmi l'hydrogène et un alkyle C1-4 ;
    R5 est l'hydrogène, alkyle C1-4, un halogène, ou le trifluorométhyle;
    R6 est alkyle C1-4 ;
    X est soit l'oxygène soit du soufre ; et
    le groupe phénylméthyl (benzyl) est attaché à la position 3 ou 4 du cycle pipéridine.
  2. Composé selon la revendication 1 choisi dans le groupe comprenant :
    la 1-Acétyl-4-[(2-Fluoro-5-méthoxyphényl)méthyl]pipéridine ;
    la 4-[(2-Fluoro-5-méthoxyphényl)méthyl]-1-(2-méthyl-1-oxopropyl) pipéridine :
    la 4-[(2-Fluoro-5-méthoxyphényl)méthyl]-1-(1-oxobutyl)pipéridine ;
    la 4-[(2-Fluoro-5-méthoxyphényl)méthyl]-1-(1-oxopropyl)pipéridine ;
    la 4-[(2-Fluoro-5-méthoxyphényl)méthyl]-1-(1-oxo-2-propényl)pipéridine ;
    la (E)-4-[(2-Fluoro-5-méthoxyphényl)méthyl]-1-(1-oxo-2-butényl)pipéridine ; et
    la 4-[(2-Fluoro-5-méthoxyphényl)méthyl]-1-(2-méthyl-1-oxobutyl) pipéridine ;
  3. Composé selon la revendication 1 choisi dans le groupe comprenant :
    la 1-(Cyclopropylcarbonyl)-4-[(2-Fluoro-5-méthoxyphényl)méthyl] pipéridine ;
    la 1-(Cyclobutylcarbonyl)-4-[(2-Fluoro-5-méthoxyphényl)méthyl] pipéridine ; et
    la 1-(Cyclopentylcarbonyl)-4-[(2-Fluoro-5-méthoxyphényl)méthyl] pipéridine ;
  4. Composé selon la revendication 1 choisi dans le groupe comprenant :
    le 4-[(2-Fluoro-5-méthoxyphényl)méthyl]-N,N-diméthyl-1-pipéridinecarboxamide;
    le 4-[(2-Fluoro-5-méthoxyphényl)méthyl]-N-méthyl-1-pipéridinecarboxamide;
    le 4-[(2-Fluoro-5-méthoxyphényl)méthyl]-N-propyl-1-pipéridinecarboxamide;
    le N-Ethyl-4-[(2-Fluoro-1-méthoxyphényl)méthyl]-1-pipéridinecarboxamide ; et
    l'amide d'acide 4-[(2-Fluoro-5-méthoxyphényl)méthyl]-N-propyl-1-pipéridinecarbothioïque ;
  5. Composé selon la revendication 1 choisi dans le groupe comprenant :
    la 1-(Cyclopropylcarbonyl)-4-[(3-méthoxyphényl)méthyl]pipéridine ;
    la 4-[(3-Méthoxyphényl)méthyl]-1-(1-oxobutyl)pipéridine ;
    le N-Ethyl-4-[(3-méthoxyphényl)méthyl]-1-pipéridinecarboxamide ;
    le 4-[(3-méthoxyphényl)méthyl]-N-méthyl-1-pipéridinecarboxamide :
    la 3-[(3-méthoxyphényl)méthyl]-1-(1-oxobutyl)pipéridine ; et
    le N-Ethyl-3-[(3-méthoxyphényl)méthyl]-1-pipéridinecarboxamide.
  6. Composé selon la revendication 1, qui est la :
    1-(Cyclopropylcarbonyl)-4-[(2-fluoro-1-méthoxyphényl)méthyl] pipéridine.
  7. Composé selon la revendication 1, qui est la :
    1-(Cyclopropylcarbonyl)-4-[(3-méthoxyphényl)méthyl]pipéridine.
  8. Composé selon la revendication 1, qui est le :
    N-Ethyl-[(2-Fluoro-5-méthoxyphényl)méthyl]-1-pipéridinecarboxamide.
  9. Composition pharmaceutique pour traiter un trouble du rythme circadien ou du sommeil chez un patient en ayant besoin, comprenant une quantité efficace d'un composé de la revendication 1 et une quantité appropriée d'un véhicule pharmaceutiquement acceptable.
  10. Utilisation d'une quantité efficace du composé de la revendication 1 dans la fabrication d'un médicament pour traiter un trouble du rythme circadien ou du sommeil chez un patient.
EP95402861A 1994-12-22 1995-12-18 Dérivé de 3-alkoxybenzylpiperidine utiles comme agents mélatonergique Expired - Lifetime EP0718286B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US362337 1982-03-26
US08/362,337 US5530012A (en) 1994-12-22 1994-12-22 3-alkoxybenzylpiperidine derivatives as melatonergic agents

Publications (2)

Publication Number Publication Date
EP0718286A1 EP0718286A1 (fr) 1996-06-26
EP0718286B1 true EP0718286B1 (fr) 1998-07-29

Family

ID=23425687

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95402861A Expired - Lifetime EP0718286B1 (fr) 1994-12-22 1995-12-18 Dérivé de 3-alkoxybenzylpiperidine utiles comme agents mélatonergique

Country Status (9)

Country Link
US (1) US5530012A (fr)
EP (1) EP0718286B1 (fr)
JP (1) JPH08208603A (fr)
AT (1) ATE169000T1 (fr)
AU (1) AU691057B2 (fr)
CA (1) CA2165603A1 (fr)
DE (1) DE69503745T2 (fr)
DK (1) DK0718286T3 (fr)
ES (1) ES2121617T3 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998010763A1 (fr) * 1996-09-13 1998-03-19 Merck & Co., Inc. Inhibiteurs de thrombine
FR2753706B1 (fr) * 1996-09-20 1998-10-30 Nouvelles amines cycliques n-substituees, leur procede de preparation et les compositions pharmaceutiques les renfermant
AR055916A1 (es) * 2005-04-22 2007-09-12 Wyeth Corp Derivados de dihidrobenzofurano, usos de los mismos en la preparacion de un medicamento y composicion farmaceutica
WO2007117482A2 (fr) * 2006-04-05 2007-10-18 Vitae Pharmaceuticals, Inc. Inhibiteurs de la rénine
WO2007117559A2 (fr) * 2006-04-05 2007-10-18 Vitae Pharmaceuticals, Inc. Inhibiteurs de la rénine
EP2201840B1 (fr) 2006-09-22 2011-11-02 Pharmacyclics, Inc. Inhibiteurs de la tyrosine kinase de Bruton
WO2008124582A1 (fr) * 2007-04-05 2008-10-16 Smithkline Beecham Corporation Inhibiteurs de la rénine
US20100280005A1 (en) * 2007-04-05 2010-11-04 Baldwin Jonh J Renin Inhibitors
MY191929A (en) 2010-06-03 2022-07-18 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
EP2877598A1 (fr) 2012-07-24 2015-06-03 Pharmacyclics, Inc. Mutations associées à la résistance à des inhibiteurs de la tyrosine kinase de bruton (btk)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4719219A (en) * 1982-03-30 1988-01-12 Per A. E. Carlsson Phenyl-azacycloalkanes and use thereof in treatment of central nervous system disorders
US5071875A (en) * 1989-09-25 1991-12-10 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
US5151446A (en) * 1989-09-25 1992-09-29 Northwestern University Substituted 2-amidotetralins as melatonin agonists and antagonists
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2674524B1 (fr) * 1991-03-25 1993-05-21 Adir Nouveaux amides alkyl heterocycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2680366B1 (fr) 1991-08-13 1995-01-20 Adir Nouveaux derives d'arylethylamines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
GB9216297D0 (en) * 1991-08-15 1992-09-16 Ici Plc Therapeutic agents
FR2680507B1 (fr) 1991-08-23 1993-10-08 Adir Cie Nouvelles naphtylethylurees et naphtylethylthiourees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2689124A1 (fr) 1992-03-27 1993-10-01 Adir Nouvelles naphtylalkylamines, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
WO1994000432A1 (fr) * 1992-06-30 1994-01-06 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Derives d'epinephrine anorexiques
US5449683A (en) * 1992-10-01 1995-09-12 Massachussetts Institute Of Technology Methods of inducing sleep using melatonin
FR2696453B1 (fr) * 1992-10-02 1994-12-23 Adir Nouveaux arylalkyl(thio)amides, leur procédé de préparation, et les compositions pharmaceutiques qui les contiennent.

Also Published As

Publication number Publication date
JPH08208603A (ja) 1996-08-13
EP0718286A1 (fr) 1996-06-26
ATE169000T1 (de) 1998-08-15
DE69503745T2 (de) 1999-04-29
DK0718286T3 (da) 1999-05-03
AU691057B2 (en) 1998-05-07
AU4059995A (en) 1996-06-27
CA2165603A1 (fr) 1996-06-23
ES2121617T3 (es) 1998-12-01
DE69503745D1 (de) 1998-09-03
US5530012A (en) 1996-06-25

Similar Documents

Publication Publication Date Title
EP1499589B1 (fr) Derives de n-¬phenyl(piperidin-2-yl)methyl|benzamide, leur preparation et leur application en therapeutique
US5661162A (en) 4-aminomethyl/thiomethyl/sulfonylmethyl-4-phenylpiperdines as tachykinin receptor antagonists
US7951821B2 (en) N-[phenyl(piperidin-2-yl)methyl]benzamide derivatives, preparation thereof, and use thereof in therapy
US7790753B2 (en) Derivatives of N-[phenyl(alkylpiperidine-2-yl)methyl]benzamide, preparation method thereof and application of same in therapeutics
US5300507A (en) New heterocycle-substituted alkylamides
KR20120136422A (ko) 치환된 모르폴린 및 티오모르폴린 유도체
FR2861074A1 (fr) Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
RU2124012C1 (ru) Производные индола и содержащие их фармацевтические композиции
JP2002530276A (ja) 新規なピペラジンおよびピペリジン化合物
EP0718286B1 (fr) Dérivé de 3-alkoxybenzylpiperidine utiles comme agents mélatonergique
US6211225B1 (en) Heterocyclic aminopyrrolidine derivatives as melatonergic agents
JP4322675B2 (ja) ムスカリン受容体アンタゴニストとしてのアミノテトラリン誘導体
WO2004064764A2 (fr) Peperidines amido alkyle substitues
US5252578A (en) 3-aminochroman compounds
US5726188A (en) Optically active imidazolidinone derivatives and processes for preparing them
EA015974B1 (ru) Производные пирролизина, индолизина и хинолизина, их получение и их применение в терапии
US6242448B1 (en) Trisubstituted-oxazole derivatives as serotonin ligands
JPH0552834B2 (fr)
JP2834112B2 (ja) 新規ムスカリン様レセプターアゴニスト
JP2002532472A (ja) ５−ｈｔ１ａ受容体活性を有するアリールピペリジンおよびアリール−１，２，５，６−テトラヒドロピリジン尿素誘導体
JP2002532471A (ja) ５−ｈｔ１ａ受容体活性を有するアリールピペリジンおよびアリール−１，２，５，６−テトラヒドロピリジンアミド誘導体
AU705431B2 (en) Indanylpiperidines as melatonergic agents
IL93814A (en) History of benzothiophyranilamines, their preparation and pharmaceutical preparations containing them
JPH08325254A (ja) 新規なメラトニン作動性インダニルピペラジンまたはホモピペラジン誘導体
JP2001131149A (ja) 選択的セロトニン再取り込み阻害剤

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17P Request for examination filed

Effective date: 19960928

17Q First examination report despatched

Effective date: 19970303

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

REF Corresponds to:

Ref document number: 169000

Country of ref document: AT

Date of ref document: 19980815

Kind code of ref document: T

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 69503745

Country of ref document: DE

Date of ref document: 19980903

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

ET Fr: translation filed
REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: BOVARD AG PATENTANWAELTE

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2121617

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 19981021

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20051111

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20051128

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20051204

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20051206

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20051208

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20051213

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20051214

Year of fee payment: 11

Ref country code: GB

Payment date: 20051214

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20051215

Year of fee payment: 11

Ref country code: DK

Payment date: 20051215

Year of fee payment: 11

Ref country code: DE

Payment date: 20051215

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20051228

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20051229

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20060118

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20060220

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061231

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061231

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061231

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061231

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20061231

Year of fee payment: 12

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070618

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20070618

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070701

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070703

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

EUG Se: european patent has lapsed
GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20061218

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20070701

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20070831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061218

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061218

BERE Be: lapsed

Owner name: *BRISTOL-MYERS SQUIBB CY

Effective date: 20061231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070102

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20061219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070102

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061219

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20061218

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070704

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20071218